Insulin Resistance in Multiple System Atrophy

Condition(s) studied

Investigational drug(s) / intervention(s)

Homeostasis Model Assessment of insulin resistance (HOMA): Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index

MOntreal Cognitive Assessment (MoCA): Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)

Clinical characteristics of AMS patients: Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)

Brain Magnetic Resonance Imaging (MRI): Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume

Blood sampling: Optional blood sampling for the constitution of a biological collection

Study summary

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.

Eligibility

Primary outcome measure(s)

• HOMA Index — Day 0
  Homeostasis Model Assessment of insulin resistance (HOMA) index, calculated from a fasted blood glucose and insulin level between AMS patients and a formula-controlled group (insulinemia x glycemia)/22.5 insulinemia being expressed in mU/l and glucose in mmol/L.

Trial sites (1)

More University Hospital, Bordeaux trials in France

Other trials for the same condition